Professur für Molekulare Mechanismen der Organfibrose

Reduced Decline in Forced Vital Capacity in Patients with Progressive Fibrosing Autoimmune Disease-Related Interstitial Lung Diseases (ILDs) Treated with Nintedanib (2020) Matteson E, Distler O, Distler J, Kuwana M, Pope J, Seibold J, James A, et al. Conference contribution NR4A1 AGONIST CYTOSPORONE B DOES NOT ATTENUATE CAV IN A MOUSE MODEL DESPITE REPORTED ANTI-PROLIFERATIVE AND ANTI-INFLAMMATORY EFFECTS (2020) Kuckhahn A, Ramsperger-Gleixner M, Distler J, Weyand M, Heim C Conference contribution Fibroblast growth factor receptor 3 activates a network of profibrotic signaling pathways to promote fibrosis in systemic sclerosis (2020) Chakraborty D, Zhu H, Juengel A, Summa L, Li YN, Matei AE, Zhou X, et al. Journal article Effects of nintedanib in patients with SSc-ILD and preserved and highly impaired lung function (2020) Wuyts WA, Azuma A, Distler J, Sondergaard K, Proudman S, Cottin V, Erhardt E, et al. Conference contribution INFLUENCE OF B-CATENIN ON THE PROLIFERATION OF VASCULAR SMOOTH MUSCLE CELLS AND THE DEVELOPMENT OF CARDIAC ALLOGRAFT VASCULOPATHY IN MICE (2020) Heim C, Kuckhahn A, Ramsperger-Gleixner M, Distler J, Spriewald BM, Weyand M, Ensminger SM Conference contribution Long noncoding RNA H19X is a key mediator of TGF-β-driven fibrosis (2020) Pachera E, Assassi S, Salazar GA, Stellato M, Renoux F, Wunderlin A, Blyszczuk P, et al. Journal article PGC-1α regulates autophagy to promote fibroblast activation and tissue fibrosis (2020) Zhang Y, Shen L, Zhu H, Dreissigacker K, Distler D, Zhou X, Györfi AH, et al. Journal article Racial differences in systemic sclerosis disease presentation: a European Scleroderma Trials and Research group study (2020) Jaeger VK, Tikly M, Xu D, Siegert E, Hachulla E, Airo P, Valentini G, et al. Journal article The AP1 Transcription Factor Fosl2 Promotes Systemic Autoimmunity and Inflammation by Repressing Treg Development (2020) Renoux F, Stellato M, Haftmann C, Vogetseder A, Huang R, Subramaniam A, Becker MO, et al. Journal article NINTEDANIB DOSE ADJUSTMENTS AND ADVERSE EVENTS IN PATIENTS WITH PROGRESSIVE AUTOIMMUNE DISEASE-RELATED INTERSTITIAL LUNG DISEASES IN THE INBUILD TRIAL (2020) Volkmann E, Castellvi I, Johnson S, Matteson E, Distler J, Seibold J, Costabel U, et al. Conference contribution